Abstract

HomeCirculationVol. 125, No. 8Correction Free AccessCorrectionPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessCorrectionPDF/EPUBCorrection Originally published28 Feb 2012https://doi.org/10.1161/CIR.0b013e31824da922Circulation. 2012;125:e412This article corrects the following2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary InterventionIn the article by Levine et al, “2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention,” which published ahead of print on November 7, 2011, and appeared in the December 6, 2011, issue of the journal (Circulation. 2011;124:e574–e651), several corrections were needed:On page e608, in Table 12, last row, “Argatroban,” third column, “Patient Has Not Received Prior Anticoagulant Therapy,” the dosing for argatroban read, “350 mcg/kg bolus, then 15 mcg/kg per min IV infusion.” It has been changed to read, “350 mcg/kg bolus, then 25 mcg/kg per min IV infusion.”On page e613, in the first column, first paragraph under section “5.10. Periprocedural MI Assessment: Recommendations,” the last 2 lines of the Class I recommendation read, “… creatinine kinase-MB and troponin I or T should be measured….” They have been changed to read, “… creatine kinase-MB and/or troponin I or T should be measured….” The corrected recommendation now reads, In patients who have signs or symptoms suggestive of MI during or after PCI or in asymptomatic patients with significant persistent angiographic complications (eg, large side-branch occlusion, flow-limiting dissection, no-reflow phenomenon, or coronary thrombosis), creatine kinase-MB and/or troponin I or T should be measured. (Level of Evidence: C).On page e613, in the first column, second paragraph under section “5.10. Periprocedural MI Assessment: Recommendations,” the parenthetical expression in the first and second lines of the Class IIb recommendation read, “… (creatinine kinase-MB and/or troponin I or T)….” It has been changed to read, “… (creatine kinase-MB and/or troponin I or T)….” The corrected recommendation now reads,Routine measurement of cardiac biomarkers (creatine kinase-MB and/or troponin I or T) in all patients after PCI may be reasonable. (Level of Evidence: C).These corrections have been made to the current online version of the article, which is available at http://circ.ahajournals.org/content/124/23/e574. Previous Back to top Next FiguresReferencesRelatedDetailsRelated articles2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary InterventionGlenn N. Levine, et al. Circulation. 2011;124:e574-e651 February 28, 2012Vol 125, Issue 8 Advertisement Article InformationMetrics © 2012 American Heart Association, Inc.https://doi.org/10.1161/CIR.0b013e31824da922 Originally publishedFebruary 28, 2012 PDF download Advertisement SubjectsStatements and Guidelines

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call